Abbott receives CE Mark for the TactiFlex™ Duo Ablation Catheter to treat patients with abnormal heart rhythms

1 TactiFlex Duo Supported by Strong Data CE Mark approval for the TactiFlex Duo Ablation Catheter was supported by data from Abbott's FOCALFLEX CE Mark study, a global clinical trial conducted at centers in the European Union, United Kingdom and Australia. The trial showed that TactiFlex Duo demonstrated clinically meaningful performance in the safety and effectiveness of treating patients with AFib. 2,3 Approximately eight million Europeans over the age of 65 are living with AFib, a number expected to doub ...